+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hydrocephalus Market by Cause, Type, Diagnosis, Treatment and Age: Global Opportunity Analysis and Industry Forecast, 2021-2030

  • PDF Icon

    Report

  • 280 Pages
  • December 2021
  • Region: Global
  • Allied Market Research
  • ID: 5548369
The global hydrocephalus market was valued at $6907.5 million in 2020 and is projected to reach $10178.6 million by 2030, registering a CAGR of 4.0% from 2021 to 2030.



Hydrocephalus is a chronic, neurological disorder caused by an abnormal accumulation of cerebrospinal fluid (CSF) within cavities of the brain called ventricles. This increase in volume results on elevated pressure within the cranium, which can cause irreversible damage to the brain tissue. The human body produces 500 ml of CSF on daily basis, with continuous replacement of the fluid as it is absorbed. In normal conditions, there is a subtle balance between the amount of fluid produced and the rate at which it is absorbed within the body. Hydrocephalus occurs when there is a disruption in this balance. Hydrocephalus can be treated in a variety of ways based on the aetiology of the disorder. But it is most commonly treated indirectly by implanting a medical device known as a “shunt” to divert the excess CSF away from the brain. A shunt, is a flexible tube, which is placed in the ventricular system of the brain that diverts the flow of CSF to another region of the body, most often the abdominal cavity, or heart, where it can be absorbed. Moreover, other treatment options for hydrocephalus include ventriculostomy and medications. One of the prominent factors responsible for the growth hydrocephalus market includes the increase in the number of hydrocephalic patients, which subsequently leads to the increase in the number of shunting procedures across the world. For instance, according to the hydrocephalus association, in 2021, over 36,000 shunt surgeries are performed each year (one every 15 minutes) and more than half of them represent emergencies.

Moreover, high demand for neurosurgery devices & accessories for hydrocephalus management and a rise in cases of neurological disorders, owing to congenital abnormalities and lifestyle diseases as well as a rise in incidences of brain and nerve injuries, boosts the demand for hydrocephalic shunts.

Furthermore, the key developmental strategies such as product approval, partnership, and launch of various novel hydrocephalic valves by key players are further projected to propel the growth of the market. For instance, in 2021, Anuncia Inc., an emerging leader in Cerebral Spinal Fluid (CSF) management, received U.S. Food and Drug Administration (FDA) breakthrough device designation for its ReFlow System Mini intended for the treatment of CSF disorders requiring shunting such as hydrocephalus.

Furthermore, in 2020, Aesculap, Inc., in partnership with the Christoph Miethke GmbH & Co. KG (MIETHKE), announced the launch of the M.blue valve, the latest generation of Hydrocephalus valve technology. Its unique gravitational technology is integrated with a fixed differential pressure unit in one valve, allowing for a simple, position-dependent solution. These strategies are certainly enhancing the company’s footprints in the Hydrocephalus market, thereby contributing to the overall growth of the market.

However, serious damages caused by infections and malfunctions of existing shunts greatly limit the market growth. Some deleterious complications include irreversible brain injuries, meningitis, endocarditis, traumatic perforation, tricuspid regurgitation, heart failure, pulmonary hypertension, and others. For instance, according to the Hydrocephalus Association, approximately 50% of shunts in the pediatric population fail within two years of placement, requiring repeated neurological operations. On the contrary, advancements in shunt technology for reducing shunt complications are projected to create lucrative opportunities for market growth.

The hydrocephalus market is segmented on the basis of cause, type, diagnosis, treatment, age and region. On the basis of cause, the market is categorized into congenital hydrocephalus and acquired hydrocephalus. By type, the market is segmented into communicating hydrocephalus and non-communicating hydrocephalus. The communicating hydrocephalus is categorized into normal pressure hydrocephalus, ex-vacuo hydrocephalus. The diagnosis segment is fragmented into CT scan, MRI, and ultrasound. Furthermore, on the basis of treatment, the market is categorized into surgery shunt insertion and ventriculostomy.

The age is categorized into Neonate & Pediatrics and Adults. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the global hydrocephalus shunt market are Aesculap Inc., Integra Lifesciences, Karl Storz Se And Co. Kg, Proteses Inc., Medtronic Plc. and Natus Medical Inc. Further, the service provider of hydrocephalus is Boston Children’s Hospital, Anadolu Medical Center, Helios Hospital, Texas Children's Hospital, and Children's National Hospital.

Key benefits for stakeholders

  • The study provides an in-depth analysis of the global hydrocephalus market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict market growth is provided in the report.
  • A comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps understand the different types of hydrocephalus across the globe.
  • Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

Key market segments


By Cause

  • Congenital hydrocephalus
  • Acquired hydrocephalus

By type

  • Communicating hydrocephalus
  • Normal Pressure hydrocephalus
  • Ex-vacuo hydrocephalus
  • Non- Communicating hydrocephalus

By Diagnosis

  • CT Scan
  • MRI
  • Ultrasound

By Treatment

  • Surgery shunt insertion
  • Ventriculostomy

By AGE

  • Neonate & Pediatrics
  • Adults

By Service Provider

  • Boston Children’s Hospital
  • Anadolu Medical Center
  • Helios Hospital
  • Texas Children's Hospital
  • Children's National Hospital

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

List of key players profile and Service provider in the report

  • Aesculap Inc.
  • Integra Lifesciences
  • Karl Storz Se And Co. Kg
  • Medtronic Plc
  • Natus Medical Inc.
Frequently Asked Questions about the Global Hydrocephalus Market

What is the estimated value of the Global Hydrocephalus Market?

The Global Hydrocephalus Market was estimated to be valued at $6907.5 million in 2020.

What is the growth rate of the Global Hydrocephalus Market?

The growth rate of the Global Hydrocephalus Market is 4.0%, with an estimated value of $10178.6 million by 2030.

What is the forecasted size of the Global Hydrocephalus Market?

The Global Hydrocephalus Market is estimated to be worth $10178.6 million by 2030.

Who are the key companies in the Global Hydrocephalus Market?

Key companies in the Global Hydrocephalus Market include Aesculap Inc., Integra Lifesciences, Karl Storz Se And Co. Kg, Proteses Inc. and Natus Medical Inc..

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profile and Service provider in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Growth in prevalence of hydrocephalus
3.4.1.2. Surge in adoption of hydrocephalus shunt
3.4.1.3. Increase in incidences of neurological disorders
3.4.2. Restraint
3.4.2.1. Shunt malfunction and related infections
3.4.3. Opportunity
3.4.3.1. Advancements in technology in the healthcare sector
3.5. Top player positioning
3.6. Communicating hydrocephalus: Causes, Symptoms, and Treatments
3.7. COVID-19 Impact on the market
CHAPTER 4: HYDROCEPHALUS MARKET, BY CAUSE
4.1. Overview
4.1.1. Market size and forecast
4.2. Congenital Hydrocephalus
4.2.1. Market size and forecast, by region
4.2.2. Market share analysis, by country
4.3. Acquired hydrocephalus
4.3.1. Market size and forecast, by region
4.3.2. Market analysis, by country
CHAPTER 5: HYDROCEPHALUS MARKET, BY TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Communicating hydrocephalus
5.2.1. Key market trends and growth opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market analysis, by country
5.2.4. Market size and forecast, by type
5.2.4.1. Normal pressure hydrocephalus
5.2.4.1.1. Market size and forecast
5.2.4.2. Ex-Vacuo hydrocephalus
5.2.4.2.1. Market size and forecast
5.3. Non-communicating hydrocephalus
5.3.1. Key market trends and growth opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market analysis, by country
CHAPTER 6: HYDROCEPHALUS MARKET, BY DIAGNOSIS
6.1. Overview
6.1.1. Market size and forecast
6.2. CT Scan
6.2.1. Market size and forecast, by region
6.2.2. Market share analysis, by country
6.3. MRI
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.4. Ultrasound
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country
CHAPTER 7: HYDROCEPHALUS MARKET, BY TREATMENT
7.1. Overview
7.1.1. Market size and forecast
7.2. Surgery shunt insertion
7.2.1. Market size and forecast, by region
7.2.2. Market share analysis, by country
7.3. Ventriculostomy
7.3.1. Market size and forecast, by region
7.3.2. Market analysis, by country
CHAPTER 8: HYDROCEPHALUS MARKET, BY AGE
8.1. Overview
8.1.1. Market size and forecast
8.2. Neonate and Pediatrics
8.2.1. Market size and forecast, by region
8.2.2. Market share analysis, by country
8.3. Adults
8.3.1. Market size and forecast, by region
8.3.2. Market analysis, by country
CHAPTER 9: HYDROCEPHALUS MARKET, BY REGION
9.1. Overview
9.1.1. Market size and forecast
9.2. North America
9.2.1. Key market trends, growth factors, and opportunities
9.2.2. North America market size and forecast, by cause
9.2.3. North America market size and forecast, by type
9.2.4. North America market size and forecast, by diagnosis
9.2.5. North America market size and forecast, by treatment
9.2.6. North America market size and forecast, by age
9.2.7. Market size and forecast, by country
9.2.7.1. U.S.
9.2.7.1.1. U.S. Hydrocephalus Market, by cause
9.2.7.1.2. U.S. Hydrocephalus Market, by type
9.2.7.1.3. U.S. Hydrocephalus Market, by diagnosis
9.2.7.1.4. U.S. Hydrocephalus Market, by treatment
9.2.7.1.5. U.S. Hydrocephalus Market, by age
9.2.7.2. Canada
9.2.7.2.1. Canada Hydrocephalus Market, by cause
9.2.7.2.2. Canada Hydrocephalus Market, by type
9.2.7.2.3. Canada Hydrocephalus Market, by diagnosis
9.2.7.2.4. Canada Hydrocephalus Market, by treatment
9.2.7.2.5. Canada Hydrocephalus Market, by age
9.2.7.3. Mexico
9.2.7.3.1. Mexico Hydrocephalus Market, by cause
9.2.7.3.2. Mexico Hydrocephalus Market, by type
9.2.7.3.3. Mexico Hydrocephalus Market, by diagnosis
9.2.7.3.4. Mexico Hydrocephalus Market, by treatment
9.2.7.3.5. Mexico Hydrocephalus Market, by age
9.3. Europe
9.3.1. Key market trends, growth factors, and opportunities
9.3.2. Europe market size and forecast, by cause
9.3.3. Europe market size and forecast, by type
9.3.4. Europe market size and forecast, by diagnosis
9.3.5. Europe market size and forecast, by treatment
9.3.6. Europe market size and forecast, by age
9.3.7. Market size and forecast, by country
9.3.7.1. Germany
9.3.7.1.1. Germany Hydrocephalus Market, by cause
9.3.7.1.2. Germany Hydrocephalus Market, by type
9.3.7.1.3. Germany Hydrocephalus Market, by diagnosis
9.3.7.1.4. Germany Hydrocephalus Market, by treatment
9.3.7.1.5. Germany Hydrocephalus Market, by age
9.3.7.2. France
9.3.7.2.1. France Hydrocephalus Market, by cause
9.3.7.2.2. France Hydrocephalus Market, by type
9.3.7.2.3. France Hydrocephalus Market, by diagnosis
9.3.7.2.4. France Hydrocephalus Market, by treatment
9.3.7.2.5. France Hydrocephalus Market, by age
9.3.7.3. UK
9.3.7.3.1. UK Hydrocephalus Market, by cause
9.3.7.3.2. UK Hydrocephalus Market, by type
9.3.7.3.3. UK Hydrocephalus Market, by diagnosis
9.3.7.3.4. UK Hydrocephalus Market, by treatment
9.3.7.3.5. UK Hydrocephalus Market, by age
9.3.7.4. Italy
9.3.7.4.1. Italy Hydrocephalus Market, by cause
9.3.7.4.2. Italy Hydrocephalus Market, by type
9.3.7.4.3. Italy Hydrocephalus Market, by diagnosis
9.3.7.4.4. Italy Hydrocephalus Market, by treatment
9.3.7.4.5. Italy Hydrocephalus Market, by age
9.3.7.5. Spain
9.3.7.5.1. Spain Hydrocephalus Market, by cause
9.3.7.5.2. Spain Hydrocephalus Market, by type
9.3.7.5.3. Spain Hydrocephalus Market, by diagnosis
9.3.7.5.4. Spain Hydrocephalus Market, by treatment
9.3.7.5.5. Spain Hydrocephalus Market, by age
9.3.7.6. Rest of Europe
9.3.7.6.1. Rest of Europe Hydrocephalus Market, by cause
9.3.7.6.2. Rest of Europe Hydrocephalus Market, by type
9.3.7.6.3. Rest of Europe Hydrocephalus Market, by diagnosis
9.3.7.6.4. Rest of Europe Hydrocephalus Market, by treatment
9.3.7.6.5. Rest of Europe Hydrocephalus Market, by age
9.4. Asia-Pacific
9.4.1. Key market trends, growth factors, and opportunities
9.4.2. Asia-Pacific market size and forecast, by cause
9.4.3. Asia-Pacific market size and forecast, by type
9.4.4. Asia-Pacific market size and forecast, by diagnosis
9.4.5. Asia-Pacific market size and forecast, by treatment
9.4.6. Asia-Pacific market size and forecast, by age
9.4.7. Market size and forecast, by country
9.4.7.1. China
9.4.7.1.1. China Hydrocephalus Market, by Cause
9.4.7.1.2. China Hydrocephalus Market, by type
9.4.7.1.3. China Hydrocephalus Market, by diagnosis
9.4.7.1.4. China Hydrocephalus Market, by treatment
9.4.7.1.5. China Hydrocephalus Market, by age
9.4.7.2. Japan
9.4.7.2.1. Japan Hydrocephalus Market, by cause
9.4.7.2.2. Japan Hydrocephalus Market, by type
9.4.7.2.3. Japan Hydrocephalus Market, by diagnosis
9.4.7.2.4. Japan Hydrocephalus Market, by treatment
9.4.7.2.5. Japan Hydrocephalus Market, by age
9.4.7.3. India
9.4.7.3.1. India Hydrocephalus Market, by cause
9.4.7.3.2. India Hydrocephalus Market, by type
9.4.7.3.3. India Hydrocephalus Market, by diagnosis
9.4.7.3.4. India Hydrocephalus Market, by treatment
9.4.7.3.5. India Hydrocephalus Market, by age
9.4.7.4. Australia
9.4.7.4.1. Australia Hydrocephalus Market, by cause
9.4.7.4.2. Australia Hydrocephalus Market, by type
9.4.7.4.3. Australia Hydrocephalus Market, by diagnosis
9.4.7.4.4. Australia Hydrocephalus Market, by treatment
9.4.7.4.5. Australia Hydrocephalus Market, by age
9.4.7.5. South Korea
9.4.7.5.1. South Korea Hydrocephalus Market, by cause
9.4.7.5.2. South Korea Hydrocephalus Market, by type
9.4.7.5.3. South Korea Hydrocephalus Market, by diagnosis
9.4.7.5.4. South Korea Hydrocephalus Market, by treatment
9.4.7.5.5. South Korea Hydrocephalus Market, by age
9.4.7.6. Rest of Asia-Pacific
9.4.7.6.1. Rest of Asia-Pacific Hydrocephalus Market, by cause
9.4.7.6.2. Rest of Asia-Pacific Hydrocephalus Market, by type
9.4.7.6.3. Rest of Asia-Pacific Hydrocephalus Market, by diagnosis
9.4.7.6.4. Rest of Asia-Pacific Hydrocephalus Market, by treatment
9.4.7.6.5. Rest of Asia-Pacific Hydrocephalus Market, by age
9.5. LAMEA
9.5.1. Key market trends, growth factors, and opportunities
9.5.2. LAMEA market size and forecast, by cause
9.5.3. LAMEA market size and forecast, by type
9.5.4. LAMEA market size and forecast, by diagnosis
9.5.5. LAMEA market size and forecast, by treatment
9.5.6. LAMEA market size and forecast, by age
9.5.7. Market size and forecast, by country
9.5.7.1. Brazil
9.5.7.1.1. Brazil Hydrocephalus Market, by cause
9.5.7.1.2. Brazil Hydrocephalus Market, by type
9.5.7.1.3. Brazil Hydrocephalus Market, by diagnosis
9.5.7.1.4. Brazil Hydrocephalus Market, by treatment
9.5.7.1.5. Brazil Hydrocephalus Market, by age
9.5.7.2. Saudi Arabia
9.5.7.2.1. Saudi Arabia Hydrocephalus Market, by cause
9.5.7.2.2. Saudi Arabia Hydrocephalus Market, by type
9.5.7.2.3. Saudi Arabia Hydrocephalus Market, by diagnosis
9.5.7.2.4. Saudi Arabia Hydrocephalus Market, by treatment
9.5.7.2.5. Saudi Arabia Hydrocephalus Market, by age
9.5.7.3. South Africa
9.5.7.3.1. South Africa Hydrocephalus Market, by cause
9.5.7.3.2. South Africa Hydrocephalus Market, by type
9.5.7.3.3. South Africa Hydrocephalus Market, by diagnosis
9.5.7.3.4. South Africa Hydrocephalus Market, by treatment
9.5.7.3.5. South Africa Hydrocephalus Market, by age
9.5.7.4. Rest of LAMEA
9.5.7.4.1. Rest of LAMEA Hydrocephalus Market, by cause
9.5.7.4.2. Rest of LAMEA Hydrocephalus Market, by type
9.5.7.4.3. Rest of LAMEA Hydrocephalus Market, by diagnosis
9.5.7.4.4. Rest of LAMEA Hydrocephalus Market, by treatment
9.5.7.4.5. Rest of LAMEA Hydrocephalus Market, by age
CHAPTER 10: COMPANY PROFILES
10.1. AESCULAP INC. (B. BRAUN COMPANY)
10.1.1. Company overview
10.1.2. Operating business segments
10.1.3. Product portfolio
10.1.4. Business performance
10.1.5. Key strategic moves and developments
10.2. INTEGRA LIFE SCIENCES INC.
10.2.1. Company overview
10.2.2. Operating business segments
10.2.3. Product portfolio
10.2.4. Business performance
10.2.5. Key strategic moves and developments
10.3. KARL STORZ SE AND CO. KG
10.3.1. Company overview
10.3.2. Operating business segments
10.3.3. Product portfolio
10.4. MEDTRONIC PLC
10.4.1. Company overview
10.4.2. Operating business segments
10.4.3. Product portfolio
10.4.4. Business performance
10.5. NATUS MEDICAL INCORPORATED
10.5.1. Company overview
10.5.2. Company snapshot
10.5.3. Operating business segments
10.5.4. Product portfolio
10.5.5. Business performance
CHAPTER 11: COMPANY PROFILES: SERVICE BASED
11.1. BOSTON CHILDREN’S HOSPITAL
11.1.1. Hospital overview
11.1.2. Hospital snapshot
11.2. ANADOLU MEDICAL CENTER.
11.2.1. Hospital overview
11.2.2. Hospital snapshot
11.3. HELIOS HOSPITAL
11.3.1. Hospital overview
11.3.2. Hospital snapshot
11.4. TEXAS CHILDREN'S HOSPITAL
11.4.1. Hospital overview
11.4.2. Hospital snapshot
11.5. CHILDREN'S NATIONAL HOSPITAL
11.5.1. Hospital overview
11.5.2. Hospital snapshot
List of Tables
TABLE 01. GLOBAL HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
TABLE 02. CONGENITAL HYDROCEPHALUS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 03. FOR ACQUIRED HYDROCEPHALUS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 04. HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 05. COMMUNICATING HYDROCEPHALUS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 06. COMMUNICATING HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 07. NON-COMMUNICATING HYDROCEPHALUS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 08. GLOBAL HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
TABLE 09. GLOBAL HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 (VOLUME UNITS)
TABLE 10. HYDROCEPHALUS MARKET FOR CT SCAN, BY REGION, 2020-2030 ($MILLION)
TABLE 11. HYDROCEPHALUS MARKET FOR MRI, BY REGION, 2020-2030 ($MILLION)
TABLE 12. HYDROCEPHALUS MARKET FOR HEAD ULTRASOUND, BY REGION, 2020-2030 ($MILLION)
TABLE 13. GLOBAL HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 14. HYDROCEPHALUS MARKET FOR SURGERY SHUNT INSERTION, BY REGION, 2020-2030 ($MILLION)
TABLE 15. HYDROCEPHALUS MARKET FOR VENTRICULOSTOMY, BY REGION, 2020-2030 ($MILLION)
TABLE 16. GLOBAL HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
TABLE 17. HYDROCEPHALUS MARKET FOR NEONATE AND PEDIATRICS, BY REGION, 2020-2030 ($MILLION)
TABLE 18. HYDROCEPHALUS MARKET FOR VENTRICULOSTOMY, BY REGION, 2020-2030 ($MILLION)
TABLE 19. HYDROCEPHALUS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 20. NORTH AMERICA HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
TABLE 21. NORTH AMERICA HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 22. NORTH AMERICA HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
TABLE 23. NORTH AMERICA HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 24. NORTH AMERICA HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
TABLE 25. NORTH AMERICA HYDROCEPHALUS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 26. U.S. HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
TABLE 27. U.S. HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 28. U.S. HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
TABLE 29. U.S. HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 30. U.S. HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
TABLE 31. CANADA HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
TABLE 32. CANADA HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 33. CANADA HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
TABLE 34. CANADA HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 35. CANADA HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
TABLE 36. MEXICO HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
TABLE 37. MEXICO HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 38. MEXICO HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
TABLE 39. MEXICO HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 40. MEXICO HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
TABLE 41. EUROPE HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
TABLE 42. EUROPE HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 43. EUROPE HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
TABLE 44. EUROPE HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 45. EUROPE HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
TABLE 46. EUROPE HYDROCEPHALUS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 47. GERMANY HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
TABLE 48. GERMANY HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 49. GERMANY HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
TABLE 50. GERMANY HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 51. GERMANY HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
TABLE 52. FRANCE HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
TABLE 53. FRANCE HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 54. FRANCE HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
TABLE 55. FRANCE HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 56. FRANCE HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
TABLE 57. UK HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
TABLE 58. UK HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 59. UK HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
TABLE 60. UK HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 61. UK HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
TABLE 62. ITALY HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
TABLE 63. ITALY HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 64. ITALY HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
TABLE 65. ITALY HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 66. ITALY HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
TABLE 67. SPAIN HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
TABLE 68. SPAIN HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 69. SPAIN HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
TABLE 70. SPAIN HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 71. SPAIN HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
TABLE 72. REST OF EUROPE HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
TABLE 73. REST OF EUROPE HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 74. REST OF EUROPE HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
TABLE 75. REST OF EUROPE HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 76. REST OF EUROPE HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
TABLE 77. ASIA-PACIFIC HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
TABLE 78. ASIA-PACIFIC HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 79. ASIA-PACIFIC HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
TABLE 80. ASIA-PACIFIC HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 81. ASIA-PACIFIC HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
TABLE 82. ASIA-PACIFIC HYDROCEPHALUS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 83. CHINA HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
TABLE 84. CHINA HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 85. CHINA HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
TABLE 86. CHINA HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 87. CHINA HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
TABLE 88. JAPAN HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
TABLE 89. JAPAN HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 90. JAPAN HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
TABLE 91. JAPAN HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 92. JAPAN HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
TABLE 93. INDIA HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
TABLE 94. INDIA HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 95. INDIA HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
TABLE 96. INDIA HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 97. INDIA HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
TABLE 98. AUSTRALIA HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
TABLE 99. AUSTRALIA HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 100. AUSTRALIA HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
TABLE 101. AUSTRALIA HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 102. AUSTRALIA HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
TABLE 103. SOUTH KOREA HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
TABLE 104. SOUTH KOREA HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 105. SOUTH KOREA HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
TABLE 106. SOUTH KOREA HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 107. AUSTRALIA HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
TABLE 108. REST OF ASIA-PACIFIC HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
TABLE 109. REST OF ASIA-PACIFIC HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 110. REST OF ASIA-PACIFIC HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
TABLE 111. REST OF ASIA-PACIFIC HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 112. REST OF ASIA-PACIFIC HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
TABLE 113. LAMEA HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
TABLE 114. LAMEA HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 115. LAMEA HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
TABLE 116. LAMEA HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 117. LAMEA HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
TABLE 118. LAMEA HYDROCEPHALUS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 119. BRAZIL HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
TABLE 120. BRAZIL HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 121. BRAZIL HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
TABLE 122. BRAZIL HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 123. BRAZIL HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
TABLE 124. SAUDI ARABIA HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
TABLE 125. SAUDI ARABIA HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 126. SAUDI ARABIA HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
TABLE 127. SAUDI ARABIA HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 128. SAUDI ARABIA HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
TABLE 129. SOUTH AFRICA HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
TABLE 130. SOUTH AFRICA HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 131. SOUTH AFRICA HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
TABLE 132. SOUTH AFRICA HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 133. SOUTH AFRICA HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
TABLE 134. REST OF LAMEA HYDROCEPHALUS MARKET, BY CAUSE, 2020-2030 ($MILLION)
TABLE 135. REST OF LAMEA HYDROCEPHALUS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 136. BRAZIL HYDROCEPHALUS MARKET, BY DIAGNOSIS, 2020-2030 ($MILLION)
TABLE 137. REST OF LAMEA HYDROCEPHALUS MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 138. REST OF LAMEA HYDROCEPHALUS MARKET, BY AGE, 2020-2030 ($MILLION)
TABLE 139. AESCULAP (B. BRAUN): COMPANY SNAPSHOT
TABLE 140. AESCULAP (B.BRAUN): OPERATING SEGMENTS
TABLE 141. AESCULAP (B.BRAUN): PRODUCT PORTFOLIO
TABLE 142. AESCULAP (B.BRAUN): KEY DEVELOPMENTS
TABLE 143. INTEGRA: COMPANY SNAPSHOT
TABLE 144. INTEGRA: OPERATING SEGMENTS
TABLE 145. INTEGRA: PRODUCT PORTFOLIO
TABLE 146. INTEGRA: KEY DEVELOPMENTS
TABLE 147. KARL STORZ: COMPANY SNAPSHOT
TABLE 148. KARL STORZ: OPERATING SEGMENTS:
TABLE 149. KARL STORZ: PRODUCT PORTFOLIO
TABLE 150. MEDTRONIC: COMPANY SNAPSHOT
TABLE 151. MEDTRONIC: OPERATING SEGMENTS
TABLE 152. MEDTRONIC: PRODUCT PORTFOLIO
TABLE 153. NATUS MEDICAL: COMPANY SNAPSHOT
TABLE 154. NATUS MEDICAL: OPERATING SEGMENTS
TABLE 155. NATUS MEDICAL: PRODUCT PORTFOLIO
TABLE 156. BOSTON: HOSPITAL SNAPSHOT
TABLE 157. ANADOLU MEDICAL CENTER: HOSPITAL SNAPSHOT
TABLE 158. HELIOS: HOSPITAL SNAPSHOT
TABLE 159. TEXAS CHILDREN'S HOSPITAL: HOSPITAL SNAPSHOT
TABLE 160. CHILDREN’S NATIONAL HOSPITAL: HOSPITAL SNAPSHOT
List of Figures
FIGURE 01. HYDROCEPHALUS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2017-2020*
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENTS, 2017-2020* (%)
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2017-2020*
FIGURE 06. MODERATE BARGAINING POWER OF BUYERS
FIGURE 07. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 08. HIGH THREAT OF NEW ENTRANTS
FIGURE 09. MODERATE THREAT OF SUBSTITUTION
FIGURE 10. MODERATE COMPETITIVE REIVALRY
FIGURE 11. DRIVERS, RESTRAINTS, AND OPPORTUNITY
FIGURE 12. TOP PLAYER POSITIONING, 2020
FIGURE 13. COMPARATIVE ANALYSIS OF CONGENITAL HYDROCEPHALUS MARKET, BY COUNTRY,
2020 & 2030 ($MILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF ACQUIRED HYDROCEPHALUS MARKET, BY COUNTRY,
2020 & 2030 ($MILLION)
FIGURE 15. COMPARATIVE ANALYSIS OF COMMUNICATING HYDROCEPHALUS MARKET, BY COUNTRY,
2020 & 2030 ($MILLION)
FIGURE 16. NORMAL PRESSURE HYDROCEPHALUS, 2020-2030 ($MILLION)
FIGURE 17. COMPARATIVE ANALYSIS OF HYDROCEPHALUS MARKET FOR NON-COMMUNICATING
HYDROCEPHALUS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 18. COMPARATIVE ANALYSIS OF HYDROCEPHALUS MARKET FOR CT SCAN, BY COUNTRY,
2020 & 2030 ($MILLION)
FIGURE 19. COMPARATIVE ANALYSIS OF HYDROCEPHALUS MARKET FOR MRI, BY COUNTRY,
2020 & 2030 ($MILLION)
FIGURE 20. COMPARATIVE ANALYSIS OF HYDROCEPHALUS MARKET FOR HEAD ULTRASOUND, BY COUNTRY,
2020 & 2030 ($MILLION)
FIGURE 21. COMPARATIVE ANALYSIS OF HYDROCEPHALUS MARKET FOR SURGERY SHUNT INSERTION,
BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 22. COMPARATIVE ANALYSIS OF HYDROCEPHALUS MARKET FOR VENTRICULOSTOMY, BY COUNTRY,
2020 & 2030 ($MILLION)
FIGURE 23. COMPARATIVE ANALYSIS OF HYDROCEPHALUS MARKET FOR NEONATE AND PEDIATRICS,
BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 24. COMPARATIVE ANALYSIS OF HYDROCEPHALUS MARKET FOR ADULTS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 25. B. BRAUN: NET SALES, 2018-2020 ($MILLION)
FIGURE 26. B. BRAUN: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 27. B. BRAUN: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 28. INTEGRA: NET SALES, 2018-2020 ($MILLION)
FIGURE 29. INTEGRA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 30. INTEGRA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 31. MEDTRONIC: NET SALES, 2018-2020 ($MILLION)
FIGURE 32. MEDTRONIC: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 33. MEDTRONIC: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 34. NATUS MEDICAL: NET SALES, 2018-2020 ($MILLION)
FIGURE 35. NATUS MEDICAL: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 36. NATUS MEDICAL: REVENUE SHARE, BY REGION, 2020 (%)

Companies Mentioned

  • Aesculap Inc.
  • Integra Lifesciences
  • Karl Storz Se And Co. Kg
  • Proteses Inc.
  • Medtronic Plc
  • Natus Medical Inc.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...